

Drug Monograph

Drug/Drug **INVELTYS™ (loteprednol etabonate) ophthalmic**
 Class: **suspension / Ophthalmic “Soft” Steroids**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Inveltys is a sterile preserved ophthalmic suspension containing 10 mg/mL (1%) of loteprednol etabonate.

Manufacturer: Kala Pharmaceuticals, Inc., Waltham, MA 02453

Indications: Inveltys is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Costs: \$225 per 2.8 ml bottle of INVELTYS. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications No PA Required

Prepared By: Jennifer Anderson PharmD
 Date: March 24, 2019